论文部分内容阅读
目的:研究甘精胰岛素联合格列美脲治疗2型糖尿病的临床疗效。方法:选取2011年1月~2013年1月间我院诊治的2型糖尿病患者160例,随机分为实验组(80例)和对照组(80例),其中对照组应用甘精胰岛素,实验组应用甘精胰岛素联合格列美脲治疗,治疗期间根据血糖水平调整胰岛素的用量。治疗3个月后,观察2组患者的空腹血糖、餐后2小时血糖、糖化血红蛋白、胰岛素抵抗指数以及低血糖发生率等指标。结果:治疗前,2组患者在FBG、2hFBG、HbA1c、HOMA~IR等方面无差异,治疗后2组患者均有显著的降糖效果,同时实验组胰岛素抵抗指数显著低于对照组,且低血糖发生率仅为17.50%,对照组则为37.50%。2组差异显著(P<0.05)。结论:甘精胰岛素联合格列美脲可有效控制血糖,并且能够降低胰岛素抵抗以及低血糖的发病率,可为临床治疗提供一定的参考。
Objective: To study the clinical efficacy of insulin glargine combined with glimepiride in the treatment of type 2 diabetes mellitus. Methods: A total of 160 type 2 diabetic patients diagnosed and treated in our hospital from January 2011 to January 2013 were randomly divided into experimental group (80 cases) and control group (80 cases), in which the control group was given insulin glargine, Group glargine combined with glimepiride treatment, during treatment based on blood glucose levels to adjust the amount of insulin. After 3 months of treatment, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, insulin resistance index and incidence of hypoglycemia were observed in two groups. Results: Before treatment, there was no difference in FBG, 2hFBG, HbA1c and HOMA-IR among the two groups. After treatment, both groups had significant hypoglycemic effect, and the insulin resistance index of the experimental group was significantly lower than that of the control group The incidence of blood glucose was only 17.50%, while the control group was 37.50%. There was significant difference between the two groups (P <0.05). Conclusion: Glargine and glimepiride can effectively control blood glucose, and can reduce the incidence of insulin resistance and hypoglycemia, which may provide some reference for clinical treatment.